Calcium on trial: Beyond a reasonable doubt?  by Nolan, Charles R. & Quinibi, Wajeh Y.
Letters to the Editor 383
REFERENCES To the Editor: In the July 2002 issue of Kidney Inter-
national, Chertow et al reported that treatment with1. Indridason OS, Quarles LD: Comparison of treatments for mild
sevelamer or calcium-based phosphate binders results insecondary hyperparathyroidism in hemodialysis patients. Durham
Renal Osteodystrophy Study Group. Kidney Int 57:282–292, 2000 equivalent serum phosphorus control (mean, 5.1 mg/dL).
2. Kinuta K, Tanaka H, Shinohara M, Kato S, et al: Vitamin D is This finding is surprising since mean phosphorus levelsa negative regulating factor in bone mineralization. J Bone Miner
achieved with sevelamer in previous studies were consis-Res 15(Suppl 1):S180, 2000
3. Heart Protection Study Collaborative group: MRC/BHF Heart tently above 6.0 mg/dL [1]. Moreover, we believe that
Protection Study of cholesterol lowering with simvastatin in 20,536 the study design is critically flawed since it failed to control
high-risk individuals: A randomised placebo-controlled trial. Lancet
for other variables potentially important in the progres-360:7–22, 2002
sion of cardiovascular calcification, including the type of
calcium-containing binder (calcium acetate is twice as effec-
tive as calcium carbonate yet contains half the amount ofTo the Editor: In their unblinded study of vascular
elemental calcium), dialysate calcium, vitamin D dose,calcification in dialysis patients, Chertow et al combine
and lipid levels. Did sevelamer-treated patients receive
results from patients receiving calcium acetate with those
a nighttime calcium supplement or increased dialysate
from patients receiving calcium carbonate. Use of these calcium to prevent hypocalcemia? Were there differences
calcium salts interchangeably in studies is not appro- in progression of calcification between calcium acetate-
priate since calcium acetate is a more potent phosphate and calcium carbonate-treated patients? Since vitamin D
binder with less calcium absorption [1]. This can be seen increases calcium absorption and hypercalcemia risk, and
in the study of Chertow et al by the differences in re- may itself predispose to cardiovascular calcification [2],
quired doses. If the hypothesis concerning the relation- Chertow et al should have controlled for vitamin D use.
ship of calcification to oral calcium advanced by the In the calcium-treated patients, low-density lipoprotein
authors is correct, it would be very useful to see the (LDL) cholesterol should have been controlled to an equiv-
study results analyzed for each salt separately in order alent level with 3-hydroxy-3-methylglutaryl coenzyme A
to test for dose response effects. This is particularly im- (HMG-CoA) reductase inhibitors. Given failure to ade-
portant because the average daily dose of calcium acetate quately control other important variables, this study by
required by patients in this study was nearly equivalent Chertow et al clearly does not establish a causal relation-
to the USRDA for calcium. ship between cardiovascular calcification and possible
It is likely that the sevelamer patients received supple- calcium loading from calcium-containing binders. We,
therefore, believe that this study by Chertow et al doesmental calcium (as shown by the absence of change in se-
not justify preferential use of the considerably more ex-rum calcium levels over the course of the year and that
pensive phosphate binder sevelamer hydrochloride. Fi-some also experienced hypercalcemia). Traditionally, in
nally, could the metabolic acidosis in this and other stud-studies of sevelamer, 1 gram of supplemental calcium is
ies be explained by an acid load provided by sevelameroften given to prevent hypocalcemia [2]. This dose is
hydrochloride [3].nearly equivalent to the calcium dose utilized by Cher-
tow et al in the calcium treatment arm. Clearly, there was
Charles R. Nolan and Wajeh Y. Quinibialso opportunity for adjustment of the calcium content of San Antonio, Texas
dialysis baths and vitamin D. If the sevelamer patients
Correspondence to Charles R. Nolan, M.D., Department of Medicine/did indeed receive additional calcium from supplements
Nephrology, University of Texas Health Sciences Center at San Antonio,
and dialysis solutions, conclusions concerning the culpa- 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900.
E-mail: Nolan@uthscsa.edubility of oral calcium in vascular calcification are not valid.
Mark Cleveland REFERENCES
Braintree, Massachusetts
1. Chertow GM, Burke SK, Dillon MA, et al: Long-term effects of
sevelamer hydrochloride on the calcium x phosphate product and
Correspondence to Mark Cleveland, Ph.D., Braintree Laboratories, lipid profile of haemodialysis patients. Nephrol Dial Transplant
Inc., P.O. Box 850929, Braintree, Massachusetts, USA. 14:2907–2914, 1999
E-mail: mcleveland@braintreelabs.com 2. Milliner DS, Zinsmeister AR, Lieberman E, Landing B: Soft
tissue calcification in pediatric patients with end-stage renal disease.
Kidney Int 38:931–936, 1990REFERENCES 3. Gallieni M, Cossoline M, Brancaccio D: Transient decrease of
serum bicoarbonate levels with sevelamer hydorchoride as the phos-1. Mai ML, Emmett M, Sheikh MS, et al: Calcium acetate, an effective
phage binder. Kidney Int 52:1776–1777, 2000phosphorus binder in patients with renal failure. Kidney Int 36:690–
695, 1989
2. Bleyer AJ, Burke SK, Dillon M, et al: A comparison of the Reply from the authors
calcium-free phosphate binder sevelamer hydrochloride with cal-
We are grateful to the authors of these letters for theircium acetate in the treatment of hyperphosphatemia in hemodialysis
patients. Am J Kidney Dis 33:694–701, 1999 interest in our work and to the Editor for the opportunity
